HomeAI · summaries
Storia in 3 fonti
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - GSK (NYSE:GSK), S
FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late 2026. See market reaction.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves oral Utebzi for complicated UTIs
The FDA has approved oral Utebzi tablets as a treatment for complicated urinary tract infections, including pyelonephritis, in adults with “limited or no alternative oral…
- ·
medpagetoday.com
First Oral Carbapenem Approved for Complicated UTIs
Tebipenem pivoxil proved noninferior to IV imipenem-cilastatin in hospitalized patients
